Antiretroviral treatment reduces very-low-density lipoprotein and intermediate-density lipoprotein apolipoprotein B fractional catabolic rate in human immunodeficiency virus-infected patients with mild dyslipidemia

Journal of Clinical Endocrinology and Metabolism

Volumn 90, Issue 2, 2005, Pages 755-760

  Shahmanesh, Mohsen ^a   Das, Satyajit ^a   Stolinski, Michael ^b   Shojaee Moradie, Fariba ^b   Jackson, Nicola C ^b   Jefferson, William ^b   Cramb, Robert ^a   Nightingale, Peter ^a   Umpleby, A Margot ^b  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B; DIDANOSINE; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; INTERMEDIATE DENSITY LIPOPROTEIN; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; ZIDOVUDINE;

ADULT; ARTICLE; BODY FAT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CROSS-SECTIONAL STUDIES; ETHNIC GROUPS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; LIPOPROTEINS, VLDL; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 14044272889     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2004-1273     Document Type: Article

References (35)

1. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper D 1998 A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12:F51-F58
2. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper D 1999 Diagnosis and prediction and natural course of HIV protease inhibitor (PI)-associated lipodystrophy, hyperlipidaemia and diabetes mellitus: a cohort study. Lancet 353:2093-2099
3. Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, Lang JM, Gastaut JA, Touraine JL 2000 Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 14:37-49
4. Behrens G, Dejam A, Schmidt H 1999 Impaired glucose tolerance, β cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13:F63-F70
5. Vigouroux C, Gharakhanian S, Salhi Y, Nguyen TH, Chevenne D, Capeau J, Rozenbaum W 1999 Diabetes, insulin resistance and dyslipidaemia in lipodystrophic HIV-infected patients on highly active antiretroviral therapy (HAART). Diabetes Metab 25:225-232
6. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, Pierson RN 1989 Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 86:27-31
7. Grunfeld C, Pang M, Doerrler W, Shigenaga J, Jensen P, Feingold K 1992 Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 74:1045-1052
8. Aznar R, Egido M, Puzo J, Ferrer M, Lasierra P, Cisneros P, Berdun MA, Lipid profiles in untreated HIV infected asymptomatic patients. 13th International AIDS Conference, Durban, South Africa 2000, p B758 (Abstract)
9. Dube M, Edmondson-Melancon H, Qian D, Aqeel R, Johnson D, Buchanan T 2001 Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients. J Acquir Immune Defic Syndr 27:130-134
10. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM, Locke, C, Brunzell JD 2000 Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 14:51-57
11. Noor M, Seneviratne T, Aweeka F, Lo J, Schwartz J, Milne C, Schambelan M, Grunfeld C 2002 Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 15:F1-F8
12. Petit JM, Duong M, Florentin C, Duvillard L, Chavanet P, Brun JM, Portier H, Gambert P, Verges B 2003 Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen: a stable isotope kinetic study. J Lipid Res 44:1692-1697
13. Mallal S, John M, Moore C, James I, McKinnon E 2000 Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 14:1309-1316
14. Clotet B, van der Valk M, Negredo E, Reiss P 2003 Impact of nevirapine on lipid metabolism. J Acquir Immune Defic Syndr 34 Suppl 1:S79-S84
15. Tashima KT, Bausserman L, Alt EN, Aznar E, Flanigan TP 2003 Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. HIV Clin Trials 4:29-36
16. Aldeen T, Wells C, Hay P, Davidson F, Lau R 1999 Lipodystrophy associated with nevirapine-contaming antiretroviral therapies. AIDS 13:865-867
17. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419
18. Duvillard L, Pont F, Florentin C, Calland-Jos P, Gambert P, Verges B 2000 Metabolic abnormalities of apolipoprotein B containing lipoproteine in non-insulin dependant diabetes: a stable isotope kinetic study. Eur J Clin Invest 30:685-694
19. Pearson TC, Guthrie DL, Simpson J, Chinn S, Barosi G, Ferrant A Lewis SM, Najean Y 1995 Interpretation of measured red cell mass and plasma volume in adults: Expert Panel on Radionuclides of the International Council for Standardization in Haematology. Br J Haematol 89:748-756
20. Safrin S, Grunfield C 1999 Fat distribution and metabolic changes in patients with HIV-infection. AIDS 13:2493-2505
21. Carr A, Emery S, Law M, Puls R, Lundgren JD, Powderly WG 2003 HIV Lipodystrophy Case Definition Study Group. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet 361:726-735
22. Brinkman K, Smeitink J, Romijn J, Reiss P 1999 Mitochondrial toxicity induced by nucleoside-analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy related lipodystrophy. Lancet 353:1112-1115
23. van der Valk M, Gisolf E, Reiss P, Wit FW, Japour A, Weverling G, Danner S 2001 Increased risk of lipodystrophy when nucleoside analogue transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 15:F11-F18
24. Lichtenstein KA, Delaney KM, Armon C, Ward DJ, Moorman AC, Wood KC, Holmberg SD, HIV Outpatient Study Investigators 2003 Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. J Acquir Immune Defic Syndr 32:48-56
25. Mahajan A, Tashima K, Bausserman L, Flynn M, Carpenter C 2002 Plateau in body habitus changes and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy: a 3.5-year study. J Acquir Immune Defic Syndr 28:332-335
26. Yarasheski KE, Tebas P, Claxton S, Marin D, Coleman T, Powderly WG, Semenkovich CF 2003 Visceral adiposity, C-peptide levels, and low lipase activities predict HIV-dyslipidemia. Am J Physiol 285:E899-E905
27. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio MA, Pradier C, Morfeldt L, Mateu S, Law M, El Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD, DAD study group 2003 Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy. Results from the DAD study. AIDS 17:1179-1193
28. Mauss S, Stechel J, Willers R, Schmutz G, Berger F, Richter WO 2003 Differentiating hyperlipidaemia associated with antiretroviral therapy. AIDS 17: 189-194
29. Kannisto K, Sutinen J, Korsheninnikova E, Fisher RM, Ehrenborg E, Gertow K, Virkamaki A, Nyman T, Vidal H, Hamsten A, Yki-Jarvinen H 2003 Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor γ co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS 1753-1762
30. Eckel RH 1989 Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 320:1060-1068
31. Broedl UC, Maugeais C, Millar JS, Jin W, Moore RE, Fuki IV, Marchadier D, Click JM, Rader DJ 2004 Endothelial lipase promotes the catabolism of ApoB-containing lipoproteins. Circ Res 94:1554-1561
32. Despres J-P, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C 1990 Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Atherosclerosis 10:497-511
33. Schmitz M, Michl G, Walli R, Bogner J, Bedynek A, Seidel D, Goebel FD, Demant T 2001 Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. J Acquir Immune Defic Syndr 26:225-235
34. Reeds DN, Mittendorfer B, Patterson BW, Powderley WG, Yarasheski KE, Klein S 2003 Alterations in lipid kinetics in men with HIV-dyslipidemia. Am J Physiol 285:E490-E497
35. Cummings MH, Watts GF, Umpleby AM, Hennessey TR, Naoumova R, Slavin BM, Thompson GR, Sonksen PH 1995 Increased hepatic secretion of very low density lipoprotein apolipoprotein B100 in NIDDM. Diabetologia 38:959-967